|
|
|
International Clinical Trials
|
For many patients across a wide range of therapeutic areas, participation in a clinical trial can provide access to important life-saving medications. However, the efficient conduct of studies has long been complicated by complex protocols, inefficient recruiting methods and logistics that can make participation burdensome, if not impossible. Consequently, numerous trial sponsors, CROs, and clinical services companies are striving to facilitate patient access to studies while also making the trials themselves more patient-centric. In addition to improving recruitment processes and easing the burden of participation, such efforts are largely designed to enhance patient engagement before, during, and after the study.
While the challenges surrounding patient access, retention, and engagement are not new, surmounting these requires new approaches to trial design and administration. Already, some sponsors and CROs are incorporating patient input into study design to align clinical endpoints with patients’ priorities for health outcomes. On the legislative front, citizens and lawmakers in several US states are seeking to pass ‘right to try’ laws intended to enhance access to experimental drugs, especially for terminally ill patients. Nonetheless, such initiatives will not be sufficient unless they are accompanied by efforts that improve the patient experience.
Transportation Resolutions Historically, transportation costs have constituted a very small portion of clinical trial expenses. However, when patients lack reliable transportation, this can lead to noshows and dropouts, which significantly impact study costs and results (1). A National Research Council report identified inadequate transportation as a major contributor to a 30% dropout rate in Phase 3 trials, noting that the problem worsened over the course of lengthy trials (1,2). Factors such as travel distance and intensive trial-related testing schedules are often cited as barriers to participation, especially among patients considered for lengthier trials and the elderly, as well as for those with challenging disease profiles for whom transportation can be very difficult (3).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Standardized Syringe Testing with Zwick
In today's world, the medical industry is continually faced with the challenge of providing patients with better care. Glass syringes that deliver drugs to patients are an essential part of this care. These glass syringes are typically used in connection with injection needles, needless Luer locks, adapters, and transfer devices.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014
Synergy Research Group
The Orange Paper is an analytical report about the clinical trials
market in Russia, published quarterly by the contract research
organization Synergy Research Group. The first edition of Orange Paper
was released in 2006, and at the moment 31 issues have already
published. Now, thanks to Synergy Group Ukraine, obtaining information
about the market of clinical trials in Ukraine has become possible.
In
Ukraine, during the period from 1996 to 2013, applicants had obtained
3,864 positive conclusions about the possibility of conducting clinical
trials of drugs, both for domestic and foreign manufacturers, including
conduct of multinational multi-center clinical trials (hereinafter –
MMCTs)
More info >> |
|
 |
Industry Events |
 |
RDD Asia 2018
14-15 November 2018, Grand Hyatt Kochi, Kerala, India
A
must-attend meeting for pulmonary and nasal researchers, inhaled product
developers and vendors active in this important pharmaceutical niche.
More info >> |
|
|
